Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

50.9K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
50.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

13.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.3K
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of a Genetic Variant in <i>BARD1</i> in Subjects Undergoing Germline Testing for Hereditary Tumors.

Biomedicines·2025
Same author

GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation.

EMBO reports·2025
Same author

A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a <i>STRN-ALK</i> fusion by artificial intelligence and molecular modelling: a case report.

Translational lung cancer research·2025
Same author

A Transcriptomic Analysis of Laryngeal Dysplasia.

International journal of molecular sciences·2024
Same author

Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients.

Cancers·2023
Same author

Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience.

Genes·2023

Related Experiment Video

Updated: Oct 18, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.8K

Breast Cancer Heterogeneity.

Caterina Fumagalli1, Massimo Barberis1

  • 1Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.

Diagnostics (Basel, Switzerland)
|September 28, 2021
PubMed
Summary
This summary is machine-generated.

Breast tumor heterogeneity presents challenges for personalized medicine. Evaluating metastatic biopsies and using tools like radiogenomics and liquid biopsy can help tailor breast cancer treatments.

Keywords:
breast cancerinter-tumor heterogeneityintra-tumor heterogeneity

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

Related Experiment Videos

Last Updated: Oct 18, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.8K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

Area of Science:

  • Oncology
  • Genomics
  • Medical Imaging

Background:

  • Breast cancer (BC) exhibits significant inter-tumor and intra-tumor heterogeneity, impacting patient prognosis and treatment selection.
  • Tumor progression and metastasis introduce dynamic changes, complicating personalized medicine strategies for breast cancer.

Purpose of the Study:

  • To address the challenges posed by breast cancer heterogeneity in clinical management.
  • To explore strategies for effective therapeutic decision-making in recurrent or metastatic breast cancer.

Main Methods:

  • Review of current understanding of breast tumor heterogeneity.
  • Discussion of the role of biopsies from metastatic sites for treatment assessment.
  • Exploration of radiogenomics and liquid biopsy as tools for non-invasive monitoring.

Main Results:

  • Breast cancer heterogeneity necessitates individualized treatment approaches.
  • Metastatic site biopsies are crucial for determining optimal therapy in recurrent disease.
  • Radiogenomics and liquid biopsy show promise for non-invasively assessing tumor heterogeneity and treatment response.

Conclusions:

  • Personalized medicine for breast cancer requires addressing tumor heterogeneity.
  • Dynamic monitoring of tumor progression and treatment response is essential.
  • Advanced techniques like radiogenomics and liquid biopsy can improve the management of breast cancer heterogeneity.